CAS · 254740-64-2
Product Overview
Sparsentan is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | White to off-white powder |
|---|---|
| Solubility | Soluble in DMSO |
| Identification | HPLC / HNMR |
| Particle Size | D90 < 150 μm |
| Residue on Ignition | 0.2% max |
| Heavy Metals | 10 ppm max |
| Loss on Drying | 0.5% max |
| Water Content | 0.5% max |
| Related Substances | |
| Max individual impurity | 0.5% max |
| Total impurities | 1.0% max |
| Residual Solvents | |
| Ethanol | 5000 ppm max |
| Isopropanol | 5000 ppm max |
| Dichloromethane | 600 ppm max |
| Assay (HPLC) | 98.0% – 102.0% |
Applications
Sparsentan is primarily used in the treatment of chronic kidney diseases, especially focal segmental glomerulosclerosis (FSGS) and IgA nephropathy, where it helps reduce proteinuria and slow disease progression. Its dual mechanism of action makes it more effective than traditional single-pathway therapies in managing glomerular injury and fibrosis. In clinical and pharmaceutical research, sparsentan serves as a model compound for developing next-generation dual receptor antagonists targeting both the renin–angiotensin system and endothelin pathways. It is also studied for potential applications in other fibrotic and cardiovascular conditions, where combined inhibition of vasoconstrictive and proliferative signaling pathways can provide therapeutic benefits.
Benefits
The key benefit of sparsentan lies in its dual-target mechanism, which provides enhanced efficacy compared to single receptor blockers by addressing multiple drivers of kidney damage simultaneously. This results in improved reduction of proteinuria, better preservation of kidney function, and potential slowing of disease progression. As an orally active small molecule, it offers convenient administration and good patient compliance. Its targeted pharmacological profile reduces the need for combination therapies, potentially minimizing drug interactions and simplifying treatment regimens. Additionally, its development represents progress in precision medicine, offering more effective options for patients with rare and difficult-to-treat kidney diseases.
Conclusion
Sparsentan is an innovative dual receptor antagonist with significant therapeutic potential in the treatment of chronic kidney diseases, particularly rare glomerular disorders. Its ability to simultaneously inhibit angiotensin and endothelin pathways provides improved clinical outcomes and represents a major advancement in renal pharmacotherapy. As research continues to expand its applications, sparsentan stands out as a promising drug in the evolving landscape of kidney and cardiovascular disease treatment.
Previous
4-Fluorobenzonitrile丨CAS 1194-02-1
Next